PL441360A1 - Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych - Google Patents
Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnychInfo
- Publication number
- PL441360A1 PL441360A1 PL441360A PL44136022A PL441360A1 PL 441360 A1 PL441360 A1 PL 441360A1 PL 441360 A PL441360 A PL 441360A PL 44136022 A PL44136022 A PL 44136022A PL 441360 A1 PL441360 A1 PL 441360A1
- Authority
- PL
- Poland
- Prior art keywords
- estradiol
- hydrogen peroxide
- neurodegenerative diseases
- concentration
- metabolites
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8827—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Zgłoszenie dotyczy zastosowania nadtlenku wodoru i 17β-estradiolu oraz jego metabolitów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych, zwłaszcza choroby Parkinsona charakteryzującego się tym, że sposób diagnozowania chorób neurodegeneracyjnych obejmuje analizę poziomu nadtlenku wodoru oraz pochodnych 17β-estradiolu w surowicy krwi, po ich uprzednim wyizolowaniu z krwi pacjenta i przeprowadzeniu derywatyzacji chlorkiem dansylu, przy czym chorobę neurodegeneracyjną stwierdza się, kiedy stężenie nadtlenku wodoru w badanej próbce jest wyższe od stężenia oznaczonego dla zdrowej kontroli i kiedy w badanej próbce stężenie hydroksylowanych pochodnych 17β-estradiolu jest niższe, a stężenie metoksylowanych pochodnych17β-estradiolu jest wyższe względem stężeń oznaczanych dla zdrowej kontroli.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL441360A PL249893B1 (pl) | 2022-06-02 | 2022-06-02 | Sposób diagnozowania in vitro choroby Parkinsona |
| PCT/PL2023/050040 WO2023234790A1 (en) | 2022-06-02 | 2023-05-29 | APPLICATION OF HYDROGEN PEROXIDE AND 17β-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO |
| EP23816430.5A EP4508436A4 (en) | 2022-06-02 | 2023-05-29 | APPLICATION OF HYDROGEN PEROXIDE AND 17ß-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL441360A PL249893B1 (pl) | 2022-06-02 | 2022-06-02 | Sposób diagnozowania in vitro choroby Parkinsona |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL441360A1 true PL441360A1 (pl) | 2023-12-04 |
| PL249893B1 PL249893B1 (pl) | 2026-07-13 |
Family
ID=89025328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL441360A PL249893B1 (pl) | 2022-06-02 | 2022-06-02 | Sposób diagnozowania in vitro choroby Parkinsona |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4508436A4 (pl) |
| PL (1) | PL249893B1 (pl) |
| WO (1) | WO2023234790A1 (pl) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL450034A1 (pl) * | 2024-10-15 | 2026-04-20 | Gdański Uniwersytet Medyczny | Zestaw biomarkerów oraz sposób diagnozowania in vitro nowotworu błony śluzowej trzonu macicy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0409176A2 (en) * | 1989-07-17 | 1991-01-23 | The Rockefeller University | Method and materials for detecting pathology from alterations in estrogen metabolism |
| WO2005038453A1 (en) * | 2003-10-17 | 2005-04-28 | Medvet Science Pty Ltd | Early assessment of motor recovery in spinal cord injury patients |
| WO2015161078A1 (en) * | 2014-04-17 | 2015-10-22 | The Regents Of The University Of California | Methods for comprehensive profiling of steroid metabolome |
-
2022
- 2022-06-02 PL PL441360A patent/PL249893B1/pl unknown
-
2023
- 2023-05-29 EP EP23816430.5A patent/EP4508436A4/en active Pending
- 2023-05-29 WO PCT/PL2023/050040 patent/WO2023234790A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0409176A2 (en) * | 1989-07-17 | 1991-01-23 | The Rockefeller University | Method and materials for detecting pathology from alterations in estrogen metabolism |
| WO2005038453A1 (en) * | 2003-10-17 | 2005-04-28 | Medvet Science Pty Ltd | Early assessment of motor recovery in spinal cord injury patients |
| WO2015161078A1 (en) * | 2014-04-17 | 2015-10-22 | The Regents Of The University Of California | Methods for comprehensive profiling of steroid metabolome |
Non-Patent Citations (1)
| Title |
|---|
| RIO, M.J.D., VELEZ-PARDO, C.: "Curr. Med. Chem. – Central Nervous System Agents, 2004, 4, 279-285", "THE HYDROGEN PEROXIDE AND ITS IMPORTANCE IN ALZHEIMER’S AND PARKINSON’S DISEASE" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL450034A1 (pl) * | 2024-10-15 | 2026-04-20 | Gdański Uniwersytet Medyczny | Zestaw biomarkerów oraz sposób diagnozowania in vitro nowotworu błony śluzowej trzonu macicy |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023234790A1 (en) | 2023-12-07 |
| PL249893B1 (pl) | 2026-07-13 |
| EP4508436A4 (en) | 2025-08-13 |
| EP4508436A1 (en) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maggio et al. | Associations among obesity, blood pressure, and left ventricular mass | |
| Mirick et al. | Melatonin as a biomarker of circadian dysregulation | |
| Shirtcliff et al. | Salivary cortisol results obtainable within minutes of sample collection correspond with traditional immunoassays | |
| Morrow | The isoprostanes: their quantification as an index of oxidant stress status in vivo | |
| Alamdari et al. | High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein | |
| ES2669620T3 (es) | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan | |
| CN103163306A (zh) | 25羟维生素d检测试剂盒及其制备方法 | |
| Samouda et al. | Adding anthropometric measures of regional adiposity to BMI improves prediction of cardiometabolic, inflammatory and adipokines profiles in youths: a cross-sectional study | |
| Holland et al. | Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) | |
| De Sio et al. | Work-related stress and cortisol levels: is there an association? Results of an observational study | |
| Cui et al. | Associations of exposure to per-and polyfluoroalkyl substances mixture with the numbers of lymph nodes in colorectal cancer patients | |
| Kivlighan et al. | Blood contamination and the measurement of salivary progesterone and estradiol | |
| Mahmoud et al. | Is inhibin B involved in the toxic effect of lead on male reproduction? | |
| WO2009008511A1 (ja) | 正常眼圧緑内障モデル及びそれを用いた被験物質の評価方法 | |
| Wu et al. | Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases | |
| Verburg et al. | Prevalence of thyroid disorders in elderly people in Germany | |
| du Plessis et al. | The relationship of circulating homocysteine with fibrinogen, blood pressure, and other cardiovascular measures in African adolescents | |
| Hertweck et al. | Ferriman-Gallwey scores, serum androgen and mullerian inhibiting substance levels in hirstute adolescent girls | |
| Lee et al. | Elevated blood pressure in children with cerebral palsy and its relationship with adiposity and physical activity | |
| Özyurt et al. | Elevated neurotensin levels among obese adolescents may be related to emotion dysregulation and impulsivity: a cross-sectional, case-control study | |
| Işik et al. | Aging and voice: a pilot study investigating aerodynamic and acoustic measurements in older adults | |
| Moseby-Knappe et al. | Biomarkers of brain injury after cardiac arrest; a statistical analysis plan from the TTM2 trial biobank investigators | |
| Slob et al. | The effect of acute noise exposure on the excretion of corticosteroids, adrenalin and noradrenalin in man | |
| Abdulateef | Correlation of serum prolactin with sleep duration, wake-up hour, and phases of the menstrual cycle in healthy adult subjects | |
| Leo et al. | Modulation of red blood cell nitric oxide synthase phosphorylation in the quiescent and exercising human forearm |